Abstract
The hematopoietic growth factors (HGFs) are a family of glycoproteins which plays a major role in the proliferation, differentiation, and survival of primitive hematopoietic stem and progenitor cells, and in the functions of some mature cells. More than 20 different molecules of HGF have been identified. Among them, granulocyte colony-stimulating factor (G-CSF) and granulocyte-macrophage colony-stimulating factor (GM-CSF) have been demostrated to be effective in reducing the incidence of febrile neutropenia when administered inmediately after chemotherapy and as supportive therapy in patients undergoing bone marrow transplantation. Chemotherapy used for treatment of cancer often causes neutropenia, which may be profound, requiring hospitalization, and leading to potentially fatal infection. The uses of the recombinant human hematopoietic colony-stimulating factors G-CSF and GM-CSF for treatment and prophylaxis of chemotherapy-induced febrile neutropenia will be reviewed here.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Holter JL, Ozer H. Hematopoietic Therapy: Hematopoietic Growth Factors. In: DeVita, VT Jr, Hellman S, Rosenberg SA, editors. Cancer: Principles and Practice of Oncology (ed 7). Philadelphia, PA: Lippincott Williams & Wilkins, 2001, p. 2442–59.
Freyer G, Ligneau B, Trillet-Lenoir V. Colony-stimulating factors in the prevention of solid tumors induced by chemotherapy inpatients with febrile neutropenia. Int J Antimicrob Agents. 1988;10:3–9.
Lyman GH, Kuderer NM, Djulbegovic B. A meta-analysis of granulocyte colony-stimulating factor (rH-G-CSF) to prevent febrile neutropenia (FN) in patients receiving cancer chemotherapy. Am J Med. 2002;112:406–11.
Root RK, Dale DG. Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor: comparisons and potential for use in the treatment of infections in noneutropenic patients. J Infect Dis. 1999;179 Suppl 2: S542–52.
Anaissie EJ, Vartivarian S, Bodey GP, et al. Randomized comparison between antibiotics alone and antibiotics plus granulocyte-macrophage colony-stimulating factor (Escherichia coli-derived) in cancer patients with fever and neutropenia. Am J Med. 1996;100:17–23.
Maher DW, Lieschke GJ, Green M, et al. Filgrastim in patients with chemotherapy induced febrile neutropenia: A double-blind, placebo-controlled trial. Ann Intern Med. 1994;121:492–501.
Riikonen P, Saarinen UM, Makipernaa A, et al. Recombinant human granulocyte-macrophage colony-stimulating factor in the treatment of febrile neutropenia: A double blind placebo-controlled study in children. Pediatr Infect Dis J. 1994;13:197–202.
Ravaud A, Chevreau C, Cany L, et al. Granulocyte-Macrophage colony-stimulating factor inpatients with neutropenic fever is potent after low-risk but not after high-risk neutropenic chemotherapy regimens: Results of a randomized phase III trial. J Clin Oncol. 1998;16:2030–6.
Mayordomo JI, Rivera F, Diaz-Puente MT, et al. Improving treatment of chemotherapy-induced neutropenic fever by administration of colony-stimulating factors. J Natl Cancer Inst. 1995;87:803–8.
Vellenga E, Uyl-de Groot CA, de Wit R, et al. Randomized placebo-controlled trial of granulocyte-macrophage colony-stimulating factor in patients with chemotherapy-related febrile neutropenia. J Clin Oncol. 1996;14:619–27.
Ozer H, Armitage JO, Bennet CL, et al. 2000 update of recommendations for the use of hematopoietic colony-stimulating factors: Evidence-based, clinical practice guidelines-American Society of Clinical Oncology Growth Factors Expert Panel. J Clin Oncol. 2000;18:3558–85.
Hughes WT, Armstrong D, Bodey GP, et al. 1997 Guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. Clin Infect Dis. 1997;25:551–75.
Crawford J, Ozer H, Stoller R, et al. Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Engl J Med. 1991;325:164–70.
Pettengell R, Gurney H, Radford JA, et al. Granulocyte colony-stimulating factor to prevent dose-limiting neutropenia in non-Hodgkin's lymphoma: A randomized controlled trial. Blood. 1992;80:1430–6.
Trillet-Lenoir V, Green J, Manegold C, et al. Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapy. Eur J Cancer, 1995;29A:319–24
Gerhartz HH, Engelhard M, Meusers P, et al. Randomized, double-blind, placebo-controlled, phase III study of recombinant human granulocyte-macrophage colony-stimulating factor as adjunct to induction treatment of high-grade malignant non-Hodgkin's lymphomas. Blood. 1995;82:2529–39.
Lyman GH, Kuderer NM, Djulbegovic B. Prophylactic granulocyte colony-stimulating factor impatients receiving dose-intensive cancer chemotherapy: a meta-analysis. Am J Med. 2002;112:406–11.
Pettengell R, Gurney H, Radford JA, et al. Granulocyte colony-stimulating factor to prevent dose-limiting neutropenia in non-Hodgkin's lymphoma: A randomized controlled trial. Blood. 1992;80:1450–6.
Lyman GH. Guidelines of the National Comprehensive Cancer Network on the use of Myeloid Growth, Factors with cancer chemotherapy: a review of evidence. JNCCN, 2005;3:557–71.
Kuderer NM, Crawford J, Dale CD, et al. Meta-analysis of prophylactic granulocyte colony-stimulating factor (G-CSF) in cancer patients receiving chemotherapy. J Clin Oncol. 2005;25(16S):S758.
Cosler LE, Eldar Lissai A, Dale DC, et al. Economic analysis of pegfilgastrim inpatients receiving cancer chemotherapy. J Clin Oncol. 2005;23 Suppl 15:S538.
Nichols CR, Fox EP, Roth BJ, et al. Incidence of neutropenic fever in patients treated with standard-dose combination chemotherapy for small-cell lung cancer and the cost impact of treatment with granulocyte colony-stimulating factor. J Clin Oncol. 1994;12:1245–50.
Hartmann LC, Tschetter LK, Habermann TM, et al. Granulocyte colony-stimulating factor in severe chemotherapy-induced afebrile neutropenia. N Engl J Med. 1997; 335:1776–80.
Stone RM, Berg DT, Goerge SL, et al. Granulocyte-macrophage colony-stimulating factor after initial chemotherapy, for elderly patients with primary acute myelogenous leukemia. N Engl J Med 1995;332:1671–7.
Godwin JE, Kopecky KJ, Head DR, et al. A double-blind placebo-controlled trial of granulocyte colony-stimulating factor in elderly patients with previously untreated acute myeloid leukemia: A Southwest Oncology Group study. Blood. 1989;91:3607–15
Heil G, Hoelzer MA, Sanz MA, et al. A randomized, double-blind, placebo-controlled, phase III study of filgrastim in remission induction and consolidation therapy for adults with de novo acute myeloid Leukemia. The International Acute Myeloid Leukemia Study Group. Blood. 1997;90;4710–8.
Rowe JM, Andersen JW, Mazza JJ, et al. A randomized placebo-controlled phase III study of granulocyte- macrophage colony-stimulating factor in adult patients (>55 to 70 years of age) with acute myelogenous leukemia: A study of the Eastern Cooperative Oncology Group (E1490). Blood. 1995;86:457–62.
Dombret H, Chastang C, Fenaux P, et al. A controlled study of recombinant human granulocyte colony-stimulating factor in elderly patients after treatment for acute myelogenous leukemia. AML Cooperative Study Group. N Engl J Med. 1995;332:1678–83.
Lowenberg B, Suciu S, Archimbaud E, et al. Use of recombinant GM-CSF during and after remission induction chemotherapy in patients aged 61 years and older with acute myeloid leukemia: final report of AML-11, a phase III randomized study of the Leukemia Cooperative Group of European Organisation for the Research and Treatment of Cancer and the Dutch Belgian Hemato-Oncology Cooperative Group. Blood. 1997;90:52–61.
Witz F, Sadoun A, Perrin M-C, et al. A placebo-controlled study of recombinant human granulocyte-macrophage colony-stimulating factor administered during and after induction treatment for de novo acute myelogenous leukemia in elderly patients. Blood. 1998;91:2722–30.
Schmetzer HM, Gerhartz HH, Wilmanns W. GM-CSF stimulates proliferation of clonal leukemic bone marrow cells in acute myeloid leukemia (AML)in vitro. Ann Hematol. 1999;78:449–55.
Birnbaum RA, O'Marcaigh A, Warak Z, et al. Nfl and Gmecsf interact in myeloid leukemogenesis. Mol Cell. 2000;5:189–95.
Bunn PA Jr, Crowley J, Kelly K, et al. Chemoradiotherapy with or without granulocyte-macrophage colony-stimulating factor in the treatment of limited-stage small-cell lung cancer: a prospective phase III randomized study of the Southwest Oncology Group. J Clin Oncol. 1995;13:1632–41.
Clark OA, Lyman G, Castro AA, et al. Colony stimulating factors for chemotherapy induced febrile neutropenia: a meta-analysis of randomized trials. J Clin Oncol. 2004;25;4198–214
Aviles A, Guzman R, García EL, et al. Results of a randomizaed trial of granulocyte colony-stimulating factor inpatients with infection and severe granulocytopenia. Anticancer Drugs. 1996;7:392–7.
Johnson ML, Grimwood RE. Leukocyte colony-stimulating factors. A review of associated neutrophilic dermatoses and vasculitides. Arch Dermatol. 1994;130;77–81.
Brandt SJ, Peters WP, Atwater SK, et al. Effect of recombinant human granulocyte-macrophage colony-stimulating factor on hematopoietic reconstitution after high-dose chemotherapy and autologous bone marrow transplantation. N Engl J Med. 1988;318:869–76.
Glaspy JA, Baldwin GC, Robertson PA, et al. Therapy for neutropenia in hairy cell leukemia with recombinant human granulocyte colony-stimulating factor. Ann Intern Med. 1988;109:789–95.
Pietsch T, Buhrer C, Mempel K, et al. Blood mononuclear cells from patients with severe congenital neutropenia are capable of producing granulocyte colony-stimulating factor. Blood. 1991;77:1254–7.
Smith OP, Reeves BR, Kempski HM, et al. Kostmann's disease, recombinant HuG-CSF, monosomy 7 and MDS/AML. Br J Haematol. 1995:91:150–3.
Ohara A, Kojima S, Hamajima N, et al. Myelodysplastic syndrome and acute myelogenous leukemia as a late clonal complication in children with acquired aplastic anemia. Blood. 1997;90:1009–13.
Hashino S, Imamura M, Tanaka J, et al. Transformation of severe aplastic anemia into acute myeloblastic leukemia with monosomy 7. Ann Hematol. 1996;72:337–9.
Kaito K, Kobayashi M, Katayama T, et al. Long-term administration of G-CSF for aplastic anaemia is closely related to the early evolution of monosomy 7 MDS in adults. Br J Haematol. 1998;103:297–303.
Gribben JG, Devereux S, Thomas NS, et al. Development of antibodies to unprotected glycosylation sites on recombinant human GM-CSF. Lancet. 1990;335:434–7.
Koyanagi Y, O'Brien WA, Zhao JQ, et al. Cytokines alter production of HIV-1 from primary mononuclear phagocytes. Science 1988;241:1673–5.
Wang J, Rodríguez G, Oravecz T, et al. Cytokine regulation of human immunodeficiency virus type 1 entry and replication in human monocytes/macrophages through modulation of CCR5 expression. J Virol. 1998;72:7642–7.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Raposo, C.G., Marín, Á.P. & Barón, M.G. Colony-stimulating factors: clinical evidence for treatment and prophylaxis of chemotherapy-induced febrile neutropenia. Clin Transl Oncol 8, 729–734 (2006). https://doi.org/10.1007/s12094-006-0119-4
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/s12094-006-0119-4